RomanelliFJenningsHRNathARyanMBergerJ. Therapeutic dilemma: The use of anticonvulsants in human immunodeficiency virus seropositive (HIV-seropositive) individuals. Neurology2000;54:1404–7.
2.
JenningsHRRomanelliF. The use of valproic acid in HIV-positive patients. Ann Pharmacother1999;33:1113–6.
3.
MoogCKuntz-SimonGCaussin-SchwemlingCObertG. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J Gen Virol1996;77(pt 9):1993–9.
4.
WitvrouwMSchmitJCVan RemoortalBDaelemansDEsteJAVandammeAMCell type—dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Res Hum Retroviruses1997;13:187–92.
5.
SimonGMoogCObertG. Effects of glutathione precursors on human immunodeficiency virus replication. Chem Biol Interact1994;91:217–24.
6.
StaalFJRoedererMIsraelskiDMBulpJMoleLAMcShaneDIntracellular glutathione levels in T cell subsets decrease in HIV-infected individuals. AIDS Res Hum Retroviruses1992;8:305–11.
7.
Kuntz-SimonGObertG. Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication. J Gen Virol1995;76:151–8.
8.
RadsakKFuhrmannRFrankeRPSchneiderDKollerABrucherKHInduction by sodium butyrate of cytomegalovirus replication in human endothelial cells. Arch Virol1989;107:151–8.
9.
TanakaJSadanariHSatoHFukudaS. Sodium butyrate inducible replication of cytomegalovirus in human epithelial cell line. Virology1991;196:496–505.
